Earnings call transcript: Bionano Genomics sees Q1 revenue growth, stock edges up

Bionano Genomics reported Q1 2026 revenue of $6.7 million, up 4% year over year and at the high end of guidance, while reaffirming full-year revenue guidance of $30 million to $33 million and Q2 guidance of $7.5 million to $7.8 million. Consumables revenue rose 20% to $3.9 million and adjusted gross margin improved to 49% from 46%, but software revenue fell 40% and the company remains unprofitable. The stock rose 0.86% premarket, with investors likely focused on improving recurring revenue mix, reimbursement progress, and the planned retirement of senior secured convertible debt.

Analysis

The important read-through is not the modest revenue beat; it is that BNGO is trying to convert a low-quality, lumpy revenue mix into a more defensible recurring annuity while removing the capital structure overhang. If the debt retirement lands as expected, the equity should re-rate less on near-term growth and more on financing risk compression, because the market’s prior discount has been driven by dilution/solvency anxiety rather than pure operating pessimism. That said, the business still isn’t self-funding, so the stock can remain range-bound even if the next few quarters look better.

The supply constraint matters more than the headline suggests: easing bottlenecks can mechanically boost consumables shipments before demand improvement fully shows up in reported revenue. That creates a second-order risk that investors over-interpret a few quarters of acceleration as durable demand inflection, when part of the improvement may simply be inventory normalization. The stronger reimbursement backdrop is the real catalyst, but its monetization is slow-moving; adoption in clinical workflows tends to lag code changes by quarters, not weeks.

From a competitive standpoint, the likely winners are downstream users and labs that can use reimbursement to justify workflow upgrades, while legacy cytogenetics and lower-throughput testing modalities face a gradual but real volume migration threat. The contrarian point is that the market may be underestimating how much the new board/CEO framework shifts BNGO from a story-stock to a “prove-it” execution stock: upside exists, but the easy multiple expansion has to come from evidence of sustained consumable pull-through, not more publications. For LH, the read-through is neutral to modestly negative at best: if OGM adoption broadens in clinical labs, it pressures portions of the traditional diagnostics mix over time, but not enough to matter immediately.

Key Decisions for Investors

• Long BNGO common on a 3-6 month horizon only as a small tactical position; thesis is balance-sheet de-risking + consumables mix shift, but cap size because cash burn means upside is asymmetrical only if execution holds.
• Buy BNGO Jan/Apr call spreads rather than outright stock to express a de-risking re-rate; target a 2:1 to 3:1 payoff if debt retirement is confirmed and Q2/Q3 shows consumables acceleration.
• Fade post-earnings strength in BNGO with a disciplined trim into any move toward the $1.40-$1.60 area unless there is follow-through in two consecutive quarters; that zone likely prices in the easy part of the story.
• Pair trade: long BNGO / short a small basket of legacy lab diagnostics exposure for 3-6 months to isolate reimbursement-driven workflow migration; use the short leg as a hedge against broad healthcare beta.
• Avoid a structural short in LH off this print alone; if anything, keep it on a watchlist for medium-term workflow displacement risk, but the adoption curve is too slow for a clean event-driven trade today.